In the SC group, 6% of patients had at least 1 injection-site reaction reported as an adverse event. Redness at the injection site was reported by 57% of patients, but only 1% had a severe injection-site reaction. All of the reactions resolved, with a median time to resolution of 6 days.
In the question-and-answer session following the presentation, an audience member pointed out that neurotoxicity with bortezomib may not, as Dr. Moreau speculated, be related to the peak dose, because bortezomib given at a higher dose on a once-weekly schedule is associated with lower neuropathy than with lower doses given twice weekly.
The study was supported by Janssen-Cilag. Dr. Moreau disclosed that he has received honoraria from the company and from Celgene and Millennium Pharmaceuticals and has served on Millennium’s speakers bureau or scientific advisory board.